Inventiva S.A. (IVA)
| Previous Close | 9.49 |
| Open | 9.35 |
| Bid | 3.80 x 800 |
| Ask | 13.66 x 900 |
| Day's Range | 9.30 - 9.35 |
| 52 Week Range | 8.00 - 16.93 |
| Volume | |
| Avg. Volume | 5,755 |
| Market Cap | 378.907M |
| Beta (5Y Monthly) | 0.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.37 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Results of the votes of the Combined Shareholders’ Meeting of May 19, 2022
Daix (France), Long Island City (New York, United States), May 20, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with unmet medical need, today announced the results of the votes of its Combined Shareholders’ Meeting. The Combined Shareholders' Meeting was held on Thursday May 19, 2022 at 2 p.m. at Hôtel Oceania L
- GlobeNewswire
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 19 May 2022
Daix, May 19, 2022 Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l’Autorité des marchés financiers), the purpose of this description is to present the objectives and terms of the share repurchase program of Inventiva S.A. (the “Company”) as approved by the Ordinary General Meeting of May 19, 2022. Securities concerned: shares issued by Inventiva S.A. Maximum proportion of capital that may be purchased by the Company: 10% of the total number of shares comprising t
- GlobeNewswire
Inventiva reports 2022 First Quarter Financial Information and provides clinical development update
Cash position2 at €80.5m as of March 31, 2022The Group did not generate any revenue in Q1 2022Signature of a €50 million bullet credit facility agreement with the European Investment BankUpdate on lanifibranor recruitment timing for Phase III trial in patients with NASH, as well as for the two Phase II trials in patients with NAFLD and type 2 diabetes, and in combination with empagliflozine Daix (France), Long Island City (New York, United States), May 16, 2022 – Inventiva (Euronext Paris and Na
